Antineoplastic effects of simvastatin in experimental breast cancer.

Department of Medical Biology, Jessenius Faculty of Medicine, Comenius University, Martin, Slovak Republic.
Klinická onkologie: casopis Ceské a Slovenské onkologické spolecnosti 01/2011; 24(1):41-5.
Source: PubMed

ABSTRACT Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) have proven therapeutic and preventive effects on cardiovascular diseases. Preclinical evidence demonstrates tumor-suppressive effects of statins in several human neoplasias, including breast cancer.
In this study, antineoplastic effects of simvastatin in chemoprevention of N-methyl-N-nitrosourea-induced mammary carcinogenesis in female rats were evaluated. The drug was dietary administered at two concentrations--18 mg/kg (SIMVA 18) and 180 mg/kg (SIMVA 180).
Basic parameters of experimental carcinogenesis after long-term simvastatin treatment in animals were assessed. In the SIMVA 180 group, simvastatin significantly suppressed tumour frequency by 80.5% and tumour incidence by 58.5% in comparison to the controls. Higher dose simvastatin non-significantly decreased the mean tumor volume by 23.5%, as well as non-significantly lengthened the latency period by 14.5 days compared to the control animals. Simvastatin, administered at a lower dose did not change parameters of mammary carcinogenesis in comparison to the control group. Simvastatin in both treated groups significantly decreased serum levels of triacylglycerols and VLDL-cholesterol in comparison to the control animals. Compared to the controls, a significant increase in food intake by the animals was recorded in the SIMVA 18 and SIMVA 180 groups. No significant differences in the final body weight gain between the simvastatin-administered and the control group were found.
This study represents the first report of simvastatin use in experimental mammary carcinogenesis in vivo.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Statins, commonly known as 3-hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors are recognized as the foremost drug therapy to show cardioprotection in pathological conditions like dyslipidemia and hyperlipidemia by significantly reducing blood cholesterol levels. Additionally, a number of beneficial effects have been shown by statins apart from lipid lowering that are referred to as their pleiotropic effects. Simvastatin, a potent member of statins class, has been widely used for lowering blood cholesterol levels by inhibiting HMG-CoA reductase both experimentally and clinically. Simvastatin has been well documented to be an effective drug therapy for the treatment of dyslipidemias. In addition, simvastatin has been shown to possess a variety of other pleiotropic effects in way of its potentiality as a cardioprotective agent. The present review critically discusses about the various pleiotropic effects possessed by simvastatin in affording cardioprotection.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies have suggested that statins, an established drug group in the prevention of cardiovascular mortality, could delay or prevent breast cancer recurrence but the effect on disease-specific mortality remains unclear. We evaluated risk of breast cancer death among statin users in a population-based cohort of breast cancer patients. The study cohort included all newly diagnosed breast cancer patients in Finland during 1995-2003 (31,236 cases), identified from the Finnish Cancer Registry. Information on statin use before and after the diagnosis was obtained from a national prescription database. We used the Cox proportional hazards regression method to estimate mortality among statin users with statin use as time-dependent variable. A total of 4,151 participants had used statins. During the median follow-up of 3.25 years after the diagnosis (range 0.08-9.0 years) 6,011 participants died, of which 3,619 (60.2%) was due to breast cancer. After adjustment for age, tumor characteristics, and treatment selection, both post-diagnostic and pre-diagnostic statin use were associated with lowered risk of breast cancer death (HR 0.46, 95% CI 0.38-0.55 and HR 0.54, 95% CI 0.44-0.67, respectively). The risk decrease by post-diagnostic statin use was likely affected by healthy adherer bias; that is, the greater likelihood of dying cancer patients to discontinue statin use as the association was not clearly dose-dependent and observed already at low-dose/short-term use. The dose- and time-dependence of the survival benefit among pre-diagnostic statin users suggests a possible causal effect that should be evaluated further in a clinical trial testing statins' effect on survival in breast cancer patients.
    PLoS ONE 10/2014; 9(10):e110231. DOI:10.1371/journal.pone.0110231 · 3.53 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Simvastatin, a competitive inhibitor of HMG-CoA reductase widely used in the treatment and prevention of hyperlipidemia-related diseases, has recently been associated to in vitro anticancer stem cell (CSC) actions. However, these effects have not been confirmed in vivo. To assess in vivo anti-CSC effects of simvastatin, female Sprague-Dawley rats with 7,12-dimethyl-benz(a)anthracene (DMBA)-induced mammary cancer and control animals were treated for 14 days with either simvastatin (20 or 40 mg/kg/day) or soybean oil (N = 60). Tumors and normal breast tissues were removed for pathologic examination and immunodetection of CSC markers. At 40 mg/kg/day, simvastatin significantly reduced tumor growth and the expression of most CSC markers. The reduction in tumor growth (80%) could not be explained solely by the decrease in CSCs, since the latter accounted for less than 10% of the neoplasia (differentiated cancer cells were also affected). Stem cells in normal, nonneoplastic breast tissues were not affected by simvastatin. Simvastatin was also associated with a significant decrease in proliferative activity but no increase in cell death. In conclusion, this is the first study to confirm simvastatin anti-CSC actions in vivo, further demonstrating that this effect is specific for neoplastic cells, but not restricted to CSCs, and most likely due to inhibition of cell proliferation.
    Toxicologic Pathology 10/2014; DOI:10.1177/0192623314544707 · 1.92 Impact Factor